Skye Bioscience Inc. has released a corporate presentation detailing its developments in the field of obesity treatment. The company is working on pioneering the first CB1 antibody, nimacimab, which aims to address the needs of patients who do not respond to or cannot tolerate existing GLP-1 drugs. The presentation highlights the crowded nature of the GLP-1 space, noting issues with safety and adherence. It also discusses the opportunity for nimacimab to offer a combination option for additional weight loss. Skye Bioscience is focused on addressing fundamental drivers of metabolic diseases, such as increasing energy expenditure and targeting adipose tissue to reduce fat mass. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。